Qiu Liyan, Wang Junli, Ren Fang, Shen Lixiao, Li Feng
Department of Developmental Behavioral Pediatric and Children Healthcare, MOE-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, 1665 Kongjiang Rd, Shanghai, 200092, China.
Allergy Asthma Clin Immunol. 2021 Dec 13;17(1):132. doi: 10.1186/s13223-021-00636-0.
Milk protein allergy is one of the most common food allergies in infants. We aimed to test whether fecal calprotectin can be used to monitor food allergies in infants by comparing the fecal calprotectin levels in infants with a milk protein allergy before and after an intervention treatment.
The study was designed as a prospective case-control trial. Stool samples were collected at follow-up, and the concentration of fecal calprotectin was determined using an enzyme-linked immunosorbent assay. The infant's weight and length were measured.
The allergic group comprised 90 milk-allergic infants (41 boys, 49 girls), and the nonallergic group comprised 90 nonallergic infants (51 boys, 39 girls). Compared with the fecal calprotectin level in the nonallergic group (median: 141 μg/g), that in the allergic group (median: 410 μg/g) was significantly higher (z = - 9.335, p < 0.001). After two dietary interventions and treatments, the fecal calprotectin levels of the infants with a milk protein allergy at the first (median: 253 μg/g) and second follow-up visits (median: 160 μg/g) were significantly lower than those before the intervention (z = - 7.884, p < 0.001 and z = - 8.239, p < 0.001, respectively). The growth index values (LAZ and WAZ) of the infants with a milk protein allergy at the first and second follow-up visits were significantly higher than those before dietary intervention (p < 0.05). Fecal calprotectin was negatively and significantly correlated with the WLZ and WAZ at the second follow-up visit (Spearman's rho = - 0.234, p = 0.01 and Spearman's rho = - 0.193, p = 0.03, respectively).
The level of fecal calprotectin in infants with a milk protein allergy decreased after dietary intervention and seems to be a promising biological indicator for monitoring intestinal allergies.
牛奶蛋白过敏是婴儿最常见的食物过敏之一。我们旨在通过比较牛奶蛋白过敏婴儿在干预治疗前后的粪便钙卫蛋白水平，来测试粪便钙卫蛋白是否可用于监测婴儿的食物过敏。
本研究设计为前瞻性病例对照试验。随访时收集粪便样本，采用酶联免疫吸附测定法测定粪便钙卫蛋白浓度。测量婴儿的体重和身长。
过敏组包括90名牛奶过敏婴儿（41名男孩，49名女孩），非过敏组包括90名非过敏婴儿（51名男孩，39名女孩）。与非过敏组的粪便钙卫蛋白水平（中位数：141μg/g）相比，过敏组的水平（中位数：410μg/g）显著更高（z = - 9.335，p < 0.001）。经过两次饮食干预和治疗后，牛奶蛋白过敏婴儿在第一次（中位数：253μg/g）和第二次随访时（中位数：160μg/g）的粪便钙卫蛋白水平显著低于干预前（分别为z = - 7.884，p < 0.001和z = - 8.239，p < 0.001）。牛奶蛋白过敏婴儿在第一次和第二次随访时的生长指数值（身长别年龄Z评分和体重别年龄Z评分）显著高于饮食干预前（p < 0.05）。在第二次随访时，粪便钙卫蛋白与身长别体重Z评分和体重别年龄Z评分呈显著负相关（斯皮尔曼相关系数分别为- 0.234，p = 0.01和- 0.193，p = 0.03）。
牛奶蛋白过敏婴儿的粪便钙卫蛋白水平在饮食干预后降低，似乎是监测肠道过敏的一个有前景的生物学指标。
